🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Missed ASCO? Get the key insights now – fast & free 👉 high5oncologyTV: high5oncology.tv/meeting-covera… Stephen V Liu, MD Dr Riyaz Shah Frank Griesinger Martin Reck Noemi Reguart Lizza Hendriks Nicolas Girard denis Moro-Sibilot Hossein Borghaei, DO joaquim bellmunt Anders Bjartell Simon C Ignacio Duran

🫁 Lung cancer spotlight at #ASCO25! Huge thanks to Stephen V Liu, MD, Frank Griesinger, Michael Thomas, Dr Riyaz Shah, hossein borghei, Lizza Hendriks, Noemi Reguart, Nicolas Girard for sharing key updates. 👉Visit us at high5oncologyTV: high5oncology.tv/meeting-covera…

Couldn’t be happier to share this here The collaboration between HUG and the Centre Léon Bérard UniCancer_LeonBerard , praised by the Chamber of Commerce and Industry CCI France Suisse (CCIFS), has received the Swiss Development Towards France Award during the 36th edition of

Carlos Alcaraz and Jannik Sinner both have a 100% grand slam final record. One of them will lose for the very first time.

x.com/i/article/1930…

x.com/i/article/1931…

Meet this year's global faculty behind the #ILCS! 🌍 From the US to Singapore, Europe to Australia – leading experts will share key insights with our chairs Alfredo Addeo MD and Solange Peters on 26ᵗʰ September in Switzerland and live online. Insights from leaders in lung cancer 🫁

There’s a lot to discuss about small cell lung cancer. Looking forward to this discussion soon with exceptional colleagues. The field is moving forward! #LCSM

Two studies investigating efficacy of bispecific T-cell engager tarlatamab and lurbinectedin–atezolizumab combination met their primary endpoints of survival. Read the opinion by Alfredo Addeo MD in the #ESMODailyReporter 🔗 ow.ly/Qp9N50W8j2m #SCLC #LungCancer

Congratulations to the new ESMO - Eur. Oncology Nomination Committee: Drs. Noemi Reguart Nicoletta Colombo Ulrik Lassen Martin Reck Hope Rugo!

Join us IASLC on 6/27 to discuss a few of the most exciting lung cancer studies presented at #ASCO25 All data presented by primary authors of their papers, so a chance to ask all your unanswered questions in the Q&A! Dr. Luis E. Raez Giannis Mountzios Patrick Forde Dr. Rotow Dr. Chaft

ESMO - Eur. Oncology Alfredo Addeo MD We would like to inform you that your post has been published on OncoDaily.com. Thank you for sharing. oncodaily.com/blog/tarlatama…

Tarlatamab and Lurbinectedin-Atezolizumab Combination Therapy Trials Meet Survival Endpoints: Alfredo Addeo in ESMO Daily Reporter ESMO - Eur. Oncology Alfredo Addeo MD oncodaily.com/blog/tarlatama… #OncoDaily #Oncology #Cancer #Health #Medicine #MedX #MedEd #MedNews #Tarlatamab #Lurbinectedin

❓What is the incidence, severity and timing of CRS and ICANS in pts with SCLC under T-cell engagers? ❓How can we timely identify and properly manage them? 👇Register for our webinar! ⁦Solange Peters⁩ ⁦Jacob sands⁩ ⁦International Lung Cancer Summit⁩ ⁦Mehrpouya Mobin⁩

📣 #ESMO25: A place to transform the way you treat cancer. Discover innovations and collaborate with experts to advance your practice. ⏰ Register today! Early registration deadline: 16 July 2025 🔗 ow.ly/GGjj50W7zwp

🚨 TODAY Don't miss today's roundtable on the latest progress in treating small cell lung cancer with renowned experts, Solange Peters, Giannis Mountzios and Jacob sands! #ASCO25 #LCSM ⏰ 17ᵗʰ June at 5PM CEST Tune in for free ⬇️

Important to remember that patients can only benefit if they are able to tolerate it and The #COCOON data shows that proactive management of side effects reduces them and increases #QOL That Matters! #TumorBoardTuesday #LCSM

🚨 Just out in NEJM: #KEYNOTE689 💉🧠 Periop #pembrolizumab (neoadj + adj) + surgery + RT/CRT improves EFS in resectable LA-#HNSCC. First +ve phase 3 in this space! 🔥 🔹 EFS @ 3 yrs CPS ≥10: 59.8% vs 45.9% CPS ≥1: 58.2% vs 44.9% All pts: 57.6% vs 46.4% 📉 HR ~0.66–0.73 🧪 MPR:

Congrats David O Reilly on the PLAN trial: plasma-first liquid biopsy (LB) v tissue (TB) for NSCLC in🇮🇪 EJCANCER: - 138pts - 3wk⬇️in time to genomic result,LB>TB - 90% concordance - LB half the cost (micro-cost analysis) OncoAlert Beaumont RCSI Cancer Centre #LCSM ejcancer.com/article/S0959-…

#ELIXR25🍁 Poignant presentation by ALK Positive Canada President Duncan Preece, on what matters to patients & ideas for the future: - bringing care to the pt (academic-community models, e.g. Lung Health Check Ireland) - tailored education - lean into new ways, AI OncoAlert #LCSM